Polyrizon Shares Rise After FDA Meeting for PL-14
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: MarketWatch
Polyrizon Ltd. shares increased by 5.70%, crossing above the 5-day SMA, following a successful FDA pre-submission meeting for its PL-14 allergy blocker.
The meeting clarified key regulatory requirements for future submissions and set the stage for clinical trials planned for 2026. This development is expected to enhance Polyrizon's competitiveness in the growing allergy market, projected to reach $210 million by 2033.
With a commitment to innovation, Polyrizon aims to leverage its proprietary technology to meet rising market demand, positioning itself favorably in the biotechnology sector.
Analyst Views on PLRZ
About PLRZ
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
